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Abstract
Amyotrophic lateral sclerosis (ALS) is an incurable paralyzing disease character-
ized by motor neuron death and glial reactivity. Superoxide dismutase 1 (SOD1) are 
among the most frequent alterations found in around 15–20% of ALS inheritable 
forms. Mutant SOD1 murine models mimic main human ALS features and allow 
purposing that pathological mechanisms include defective communication between 
neural cells together with astrocyte preponderant roles in disease progression. Years 
ago, a subset of the most neurotoxic aberrant astrocytes (AbAs) was obtained from 
spinal cords of SOD1G93A rats. AbA cultures show an exponential growing yield 
since the early symptoms of the disease up to the terminal stages. In cultures, AbAs 
present unprecedented toxicity to motor neurons, increased proliferation, loss of 
mature astrocyte markers, as well as extreme ER stress and abundant extracellular 
matrix components. Strikingly, AbA phenotype seems to be changing along few 
passages suggesting its signaling and features may accompany disease progression. 
However, the link between main AbA features and their highest motor neuron 
toxicity is not yet completely understood. Here, we reviewed ALS underlying 
pathological mechanisms in association to AbA phenotype, to collaborate with 
identification of the most relevant processes that seem crucially involved in the 
triggering or maintenance of neurotoxicity.
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1. Introduction
This chapter will discuss the pathogenic contribution of a subtype of aberrant 
glial phenotype into the progression and output of the neurodegenerative disease 
amyotrophic lateral sclerosis (ALS). Complete understanding of neuronal and 
glial cells roles and communication is necessary to unravel disease processes and 
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mechanisms. This will further allow the improvement of more focused therapeutic 
interventions aimed at reducing disease severity and positively impact on diagnosis, 
therapeutic management, and patients’ care.
2. ALS
ALS is an adult onset neurodegenerative disease characterized by progressive loss 
of spinal, brain stem, and cortical motor neurons, leading to fatal paralysis within 
1–5 years since the onset of symptoms that include tremor, muscle weakness, and 
spasticity [1–3]. ALS affects up to 2:100,000 persons per year; has a life risk around 
1:500–1:1000; and exhibits a little predominance of men over women affected [4]. 
Although ALS is a sporadic multifactorial disease resulting from yet unknown inter-
actions among environment, genes, and epigenetic modifications, genetics seemed 
to be the predominant factor for the risk of developing the disease [5], and more 
than 10% of ALS patients are linked to inheritable genetic abnormalities. Dominant 
mutations in the mitochondrial enzyme Cu/Zn superoxide dismutase-1 (SOD1) seem 
responsible for up to 1% of the total ALS cases and about 20% of the familial types 
[4, 6, 7]. Missense mutations in the 43 kDa transactive response DNA/RNA-binding 
protein (TDP-43) [8] and in fused in sarcoma/translocated in liposarcoma (FUS/
TLS) accounted each one for up to 5% of dominantly inherited familial ALS cases 
[9, 10]. Mutations in the open reading frame 72 on chromosome 9 (C9ORF72) that 
results in up to thousands of G4C2 hexanucleotide repeats in one allele are found in 
up to 40 and 7% of the ALS familial and sporadic cases, respectively [11]. There are 
other genes involved in ALS familial subtypes, but its contribution to the disease 
is significantly lower in terms of the affected individual number. Regarding to the 
pathological pathways linking genetic abnormalities to ALS, SOD1 mutations seem to 
be related to neuronal damage because of abnormal protein folding causes unstable 
conformations, intracellular inclusion bodies or toxic oligomers, as well as pathologi-
cal interactions with several proteins [3]. TDP-43 and FUS/TLS mutations are linked 
to altered RNA processing, transport, and quality control; whereas, G4C2 repeats 
might sequestrate RNA-binding proteins impairing the regulation of the RNA targets 
[12, 13] or causing epigenetic changes that decreased C9ORF72 expression [14, 15]. 
However, up to now, it is not completely understood how single mutations in one 
protein could elicit the ALS pathological cascades and how these cascades may finally 
cause a common neuropathological hallmark that is characterized by aggregation 
and accumulation of neuronal proteinaceous inclusions that in addition, are found in 
other neurodegenerative conditions including Alzheimer disease.
2.1 Animal models and non-cell autonomous mechanisms in ALS
To understand the different pathological mechanisms involved in ALS, many 
experimental models from yeast to rodents have been developed. Whereas, models 
in lower animals are powerful genetic tools and offer advantages related to short 
life span and easy handling, distance with mammal nervous systems constitute 
major limitations when studying human neurodegeneration [16, 17]. Mice and rats 
are closer to human brain anatomy and complexity, but are not good genetic tools 
and their lifespan makes necessary the over-expression of mutant human proteins 
several-fold times to mimic the disease [4], causing the risk that the number of 
copies over-expressed influence the model by itself. In spite of this, animal models 
appear as the best approaches to study ALS patho-mechanisms, at least until the 
employment of inducible pluripotent cells obtained from human patients becomes a 
well-known and controlled technology.
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The first successful ALS models, yet under current extensive use, were devel-
oped over-expressing different single mutations of human SOD1 (SOD1G93A, 
SOD1G37R, and SOD1G85R) in mice or rats [18–20]. Most of the models that 
overexpress SOD1 present an age-dependent progressive motor syndrome that 
mimics some pathological features of the human disease [4, 20]. In addition, it 
seems that pathological features elicited do not derive from the loss of SOD1 cata-
lytic activity but from a yet unknown gain-of-function [4, 20]. Among the highest 
contributions of murine SOD1 models to the ALS knowledge is the introduction 
of the non-cell autonomous mechanism concept in which the exclusive neuronal 
presence of mutant SOD1 did not cause motor neuron death. This implies that 
motor neuron disease results from the involvement of at least two different cell 
types. Therefore, a defective cell-cell communication between motor neurons and 
surrounding glial cells seems actively participating in motor neuron death through 
not completely understood mechanisms. Pioneer works made in LoxSOD1G37R/
GFAP-Cre+ mice [21] or specifically excising the mutant SOD1 transgene from dif-
ferent glial cell types in mice [22, 23] showed that astrocytes [21] and microglial 
cells [22] play active roles in ALS progression. In support of the non-cell autono-
mous mechanisms in SOD1 models, reactive astrocytes obtained from transgenic 
rats or mice [24–26], and from patients of sporadic and familial motor neuron 
diseases [27, 28] caused neurotoxicity to motor neurons even in cases in which 
SOD1 is not involved [28].
Other ALS models in rodents were not as clear as those over-expressing 
mutated SOD1. Transgenic animals expressing mutations of TDP-43-, FUS/TLS-, 
or C9ORF72-linked ALS produced controversial results without a clear associa-
tion between each mutation and motor neuron disease, in spite of having motor 
neuron damage, proteinaceous inclusions, and astrogliosis [29, 30]. Despite these 
drawbacks, ALS models valuably contribute to make the concept that disruption at 
systemic, cellular, and molecular levels likely result in many different interacting 
mechanisms and multiple factors, and that a particular combination of factors and 
mechanisms likely determine the singularity of each case thus explains the hetero-
geneity of the human disease.
3. Contribution of aberrant glial phenotypes to ALS pathogenesis
SOD1 models support the concept of ALS as a non-cell autonomous disease 
in which the reactive astrocyte phenotypes that are produced in the injuring 
environment greatly contribute to motor neuron death. Astrocytes are the most 
abundant glial cells in the mammal brain and those responsible for the main-
tenance of CNS homeostasis [31–34]. During injury, CNS homeostasis is lost 
and astrocytes respond in a process usually called astrogliosis, in which cells 
became reactive, highly proliferative and with morphological and functional 
changes that usually result in decreased protection together with activation of 
injuring cascades to neurons and oligodendrocytes, further affecting the whole 
CNS [31–37]. Depending on the injury type and context, astrocyte response can 
become chronic causing a long lasting state characterized by glial scar, structural 
tissue rearrangement and impeded repair, as well as a permanent imbalance 
among homeostatic supportive and gain of neurotoxic functions, all potentially 
participating in the triggering and progression of several neurological diseases 
[3, 31–35, 37, 38]. Remarkably, astrocytes also contribute to maintain astrogliosis 
through autocrine and paracrine signaling [35, 38, 39], thus causing a positive 
feedback that widespread reactivity and dependent injuring cascades perpetuat-
ing CNS damage.
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A striking question that remained unanswered until recently was to know 
if all of the astrocytes that share the same injuring environment respond in the 
same way or if some of them adopt the worse aberrant phenotypes that account 
for most of the neurotoxic effects. Trying to unravel this question, when we 
were studying spinal cord astrocyte phenotypes along the symptomatic phase 
of the rat SOD1G93A ALS experimental model, we isolated a novel type of aber-
rant astrocyte-like cells (AbAs) from the spinal cord of paralytic animals whose 
number exponentially increased toward the terminal stages of the disease [40]. 
AbAs proliferated faster than astrocytes from neonates or adult wild-type rats and 
were exceptionally toxic to embryonic motor neurons grown in culture, sug-
gesting a link between their emergence and progression of the paralysis that is a 
characteristic in the SOD1G93A ALS rat model. Moreover, AbAs did not express 
distinctive markers that clearly allow distinguishing from typical astrocytes; but 
present peculiar functional and ultrastructural features that suggest a distinctive 
phenotype. Among the most remarkable features that AbAs possess, Jiménez-
Riani et al. [41] describe their permanent absence of contact inhibition that 
allowed them to grow in multiple layers and arrange in 3D-cell aggregates that 
adopt a helicoidal pattern with a central core of extracellular matrix surrounded 
by cells. In addition, AbAs cytoskeleton does not have intermediate filaments but 
a significant abundance of microtubules and mitochondria, and ER stress have a 
restricted perinuclear location suggesting disturbed organelle trafficking that may 
be associated to alteration in microtubule network or Golgi fragmentation [42]. 
Furthermore, mitochondria from AbAs are small, electron dense matrix and with 
few crests; all, comparable to what was described early in models and human ALS 
[43, 44]. AbAs also have prominent ER with extremely swollen cisternae, some of 
them degenerating, and express high levels of some ER stress markers [45–47], as 
well as abundant lipid droplets close to ER and to mitochondria. Their cytoplasm 
is enriched in diverse vesicles with abundant signs of secretion including extracel-
lular vesicles that can be distinguished by MET and SEM in cultures as well as 
expression of protein that marks secretion granules [41, 48, 49]. AbAs are also 
highly positive to the autophagy marker LC3B [50] and present cells’ autophagic 
vesicles and residual bodies [51, 52], likely showing signs of increased autophagy 
that may allow cells coping with ER stress by favoring the clearance of misfolded 
proteins [53].
Recently, we confirmed that AbAs were not isolated from the cervical spinal 
cord of paralytic animals. Instead, the cultures obtained from the cervical spinal 
cord were similar to the age-matched wild type non-transgenic rats, sharing a 
low rate of proliferation and resembling a phagocytic microglia morphology that 
persists throughout the cell culture. Similarities also include low survival along few 
passages together with absence of complete phenotypic transition to flat cells like 
astrocytes (Figure 1). Therefore, AbAs might result as a local lumbar response to 
damage, acting similar to astrocytes when react stereotypically depending on injury 
type, location, and signaling [32].
In addition, we have found that some AbAs critical features are changing 
during few passages, as occurring with their most prominent markers S100β and 
glial glutamate transporter GLT1. Meanwhile, there were no evident morpho-
logical differences between low (LP) (~4–7) and high passages (HP) (~14–18) 
(Figure 2A), since cultured AbAs proliferated without replicative senescence, 
S100β expression levels decreased ≅98% (Figure 2B), suggesting that this aberrant 
phenotype may exhibit some plasticity along time. S100β is a well-known danger-
associated molecular pattern (DAMP) which downstream trigger the transcription 
of nuclear factor NFKB that further may elicit increased expression and release of 
pro- inflammatory cytokines [54, 55]. Given that S100β appears to integrate AbAs 
5Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
cytoskeletal elements, we cannot discard that S100β downregulated expression may 
cause cytoskeleton instability, a characteristic that is linked to exacerbated prolif-
erative capacity as found in AbAs [56]. Thus, decreasing S100β might constitute a 
reinforcing proliferation feedback that may underlie AbAs invasive properties as 
disease progressed. We have also found that GLT1 expression levels also decreased 
strongly along AbAs passages (≅94%, Figure 2B), worsening its poor expression 
which can also aggravated excitotoxic damage [31].
Concurrence of all of the features makes AbAs a unique aberrant phenotype 
with unprecedented neurotoxicity, which may rely in the yet unknown combina-
tion of ER stress, lipid droplet accumulation, abundant extracellular matrix, 
secretory granules, and exacerbated proliferation. Likely, all these events causing 
the active production of proteinaceous or lipidic soluble factors that act by itself 
or reinforce the defective cell-contact properties produced by loss of contact 
inhibition [41].
Figure 1. 
Morphological appearance of AbAs throughout the cell culture. Light microscopy examination of cells isolated 
from symptomatic cervical and lumbar spinal cord of transgenic (Tg cervical SC and Tg lumbar SC) or 
age-matched non-transgenic animals (No Tg lumbar SC) at 48 h, 5 days and 2 weeks after dissection. Note that 
AbA cells are recovered only from the lumbar spinal cord of transgenic animals whereas the cultures obtained 
from the cervical spinal cord of the same animals have similar characteristics to the age-matched wild type non-
transgenic rats. Adherent cell population is heterogenous with very bright cells that resemble microglial cells and 
others elongated similar to astrocytes. Scale bar = 150 μm (first line) and 100 μm (second and third lines).
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3.1 Mechanisms that might link AbA to ALS pathogenesis
The most important cellular processes implicated in ALS pathophysiology 
include ER stress and protein clearance, neuron-glia metabolic coupling, and 
energy homeostasis [57, 58]. Among their most remarkable features, AbAs 
exhibit a hardly coping extreme ER stress, as well as lipid droplets and disturbed 
mitochondrial morphology and trafficking [41]. ER stress is produced by the 
lack of balance between protein synthesis, folding, and degradation rates [59]. 
To recover ER homeostasis, cells activate the unfolded protein response (UPR) 
that orchestrates pro-adaptive and pro-death cellular responses that include 
protein synthesis decrease except for the effectors that mediates UPR [59–61]. 
ER stress’s final outcome depends on stress duration, strength, and cell targets, 
and if not resolved, it becomes chronic and as one of the earliest perturbations in 
several neurodegenerative diseases [59]. Interestingly, ER stress is present in ALS 
Figure 2. 
Morphology and gene expression in AbAs at low and high cell passages. A. Representative light microscopy 
images of low (LP, left) and high (HP, right) passage cells from transgenic lumbar spinal cords showing their 
distinctive appearance of flatted elongated cells that appear very similar to astrocytes. Note the low number 
of bright microglial-like cells. Scale bar = 100 μm. B. Gene expression analysis in AbA cell cultures showing a 
down-regulation of S100β (left) and glutamate transporter GLT1 (right) in HP cells compared with LP cells 
(control). The expression levels for each gene were obtained by SYBR green qPCR and normalized to the actin 
transcripts. Data represent the mean ± the standard deviation for each group.
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experimental models, and is described as a predominant mechanism underlying 
motor neuron death in patients from sporadic and familial cases [46, 59, 62–66]. 
Furthermore, active UPR in AbAs may down regulate the expression of peptides 
and proteins that collaborate with neuron survival such as the most important 
cellular antioxidant defense glutathione or neurotrophins [3, 32]. Thus, although 
ER stress in AbAs did not cause their own death, it is highly probable that it affects 
neuron and oligodendrocyte survival in view of their high dependence on astro-
cyte support.
In close relationship with ER stress, AbAs are also much enriched in lipid drop-
lets that appear near to mitochondria or ER cisternae [41]. Lipid droplets originate 
from the ER and are described as having a role in ER stress and clearance of protein 
aggregates as well as in energy homeostasis [67]. Protein turnover is critical for 
ALS because a number of mutations linked to ALS affect genes directly involved in 
protein clearance and homeostasis [58]. Lipid droplets appear associated with some 
of these proteins into the cytoplasm or the nucleus [67, 68], where they appear close 
and likely associated with the nuclear-naked organelles that control transcriptional 
activity, cell senescence, and protein degradation named as promyelocytic leukemia 
nuclear bodies [67, 69, 70], which in addition are found in cell nuclei of ALS patient 
brains co-localizing with ubiquitin and proteasome components in nuclear inclu-
sions [71].
In brain, lipid droplets are found mainly in glial cells and help to provide 
fuel for neurons when energy is needed and glucose is scarce. At this time, lipid 
droplets turned over by cytoplasmic lipases and autophagy, providing fatty 
acid fuel for ATP production [67], thus playing a crucial role in the anaplerotic 
support [72]. However, overabundance of lipid droplets as seen in AbAs may 
suggest a disrupted lipid metabolism in which lipid droplets may not be digested 
thus decreasing the energy intermediate shuttle to neurons, which can influence 
motor neuron survival through limited anaplerosis. Lipidic dysfunction could 
also indirectly impact motor neuron survival as shown in mice over-expressing 
TDP-43, that beside displaying neurological symptoms and motor deficits, also 
present increased fat accumulation and adipocyte hypertrophy [73]. Conversely, 
TDP-43 depletion causes body fat reduction, increased fatty acid consumption, 
and rapid death [74], likely, because TDP-43 depletion blocks insulin-induced 
trafficking of glucose transporter Glut4 to the plasma membrane thus impairing 
glucose uptake and inducing a metabolic switch toward lipids for energy produc-
tion. This has also been reported in SOD1 mouse models in which spinal cord 
neurons display decreased glucose usage [75], and a fat-rich diet restores body 
mass, delays disease onset, and extends life expectancy [57]. Moreover, excessive 
accumulation of lipid droplets in glial cells is a hallmark in many models of neu-
rodegeneration, and it is usually linked to mitochondrial dysfunction and disease 
progression [72, 76, 77]. It also seemed enough to promote neurodegeneration by 
itself [76], therefore indicating that overabundance of lipid droplets in AbAs may 
have dual functions: for one side not only helping to the clearance of abnormal 
proteins, but also impairing anaplerotic support to neurons or even having direct 
neurotoxicity.
AbAs also show evidences of a high secretory activity, which also is described 
as being crucial to ALS neuronal damage. Although secretory granules seem a 
conserved protective response to conserve energy and allow recovery under stress 
conditions, sustained secretory activity of stress granules seems crucial to ALS 
pathogenesis [78]. Moreover, it has been demonstrated that chromogranins inter-
act and co-localize with mutated misfolded SOD1 [79]; and can eventually act as 
chaperones to promote secretion of SOD1 mutants that once released may trigger 
microgliosis and neuronal death [79].
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Absence of contact inhibition and exacerbated proliferation are other of the 
relevant features related to AbAs neurotoxic capacity. Contact inhibition that 
occurs when dividing normal cells contact adjacent ones is crucial to maintain 
tissue homeostasis [80, 81], thus constituting an important anticancer mechanism 
which lack unleashes cells to proliferate virtually unchecked. Although underly-
ing mechanisms are mostly unknown, cell contact inhibition seems to occur when 
injury disrupts intercellular contacts achieving a proliferative status leading to 
an aggressive state associated with neoplasia [82] and malignant transformation 
[81]. Thus, AbAs, absence of contact inhibition seemed directly related to their 
exacerbated proliferation and invasive behavior during the final stages of the 
disease. In addition, abundance of EM components secreted by AbA cells may 
create a non- permissive microenvironment that potentiates invasive behavior apart 
from having a direct neurotoxic influence to motor neurons, as described in ALS 
astrocytes [83–85]. No one of each proposed mechanisms seem enough to explain 
AbAs unprecedented neurotoxicity. Instead, it likely results from the concurrence 
of many pathological pathways. However, it is also possible that one or two underly-
ing mechanisms prevail over the rest and elicit most of AbAs deleterious effects. 
Identification of these prevalent mechanisms will be a valuable aid to design the 
best ALS treatment (Table 1 and Figure 3).
(i) Absence of contact inhibition
• Invasive phenotype [40, 41]
• Lack of replicative senescence [40, 86]
• Exacerbated proliferation [40, 86, 87]
(ii) Immature phenotype
• Lack of gliofilaments [40, 41]
• Defective differentiation [40, 41, 88]
(iii) Oxidative and ER stress
• Mitochondrial dysfunction [89, 90]
• Mitochondrial morphological alterations [41]
• Defective oxidative phosphorylation [89, 90]
• Dysfunction in energy homeostasis [24, 89, 91]
• Dilated ER and degenerating ER cisternae [41]
• Elevated expression of ER stress markers [41]
(iv) Altered lipid metabolism
• Abundant lipid droplets close to mitochondria & ER [41]
• Altered anaplerotic support [88]
(v) Intracellular inclusions
• Intranuclear and intramitochondrial deposits [41]
• Abundance of autophagic bodies [41]
(vi) Aberrant signaling
• Extremely neurotoxic conditioned media [40]
• Neurotoxic exosomes [90]
• Abundance of secretory vesicles and secretory body markers [41]
Table 1. 
A summary of AbAs potential pathogenic contribution to the main ALS hallmark. All of ALS main features 
are listened as (i)–(vi) together with each specific AbAs potential participation.
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4. ALS therapeutics focused on aberrant astrocytes
ALS is an old disease with a narrow offer of pharmacological approaches. 
Riluzole, an anti-glutamatergic drug, was the first compound authorized to be used 
in ALS, providing around of 3-month improvement in survival [92]. Recently, FDA 
approved the free radical scavenger edaravone, as the second compound to treat 
ALS, that seemed to have beneficial effects only on patients in an early stages of the 
disease that in addition satisfy a number of restricted criteria. In that population, 
edavarone showed a significantly smaller decline of Revised ALS Functional Rating 
Scale score compared with placebo [93]. A randomized phase III clinical trial that 
tested the effect of the tyrosine kinase inhibitor masitinib in ALS patients showed 
an improving in the functioning of ALS patients, and the combination with riluzole 
caused a delayed disease progression without adverse effects [94]. However, the 
narrow temporal windows that the two compounds approved offer obligates to 
search alternative avenues to treat the disease.
As astrocytes and microglial cells develop both protective and pathological 
functions its pharmacological targeting must be carefully evaluated. However, in 
view of the distinctive phenotype of AbAs, it seems rational to direct therapeutic 
treatments toward the control of this population during disease progression 
and ideally trying to inhibit their emergence during asymptomatic stages. AbAs 
expression of S100β at levels higher than wild type astrocytes may imply that 
they have a role in the amplification of the inflammatory response, therefore new 
anti-inflammatory drugs targeting the production of pro-inflammatory cytokines 
Figure 3. 
AbAs: Cytotoxic effects and pathological events. AbAs present mitochondrial dysfunction associated to 
oxidative stress and ER stress as well as accumulation of lipid droplets, all causing a positive feedback that elicit 
and perpetuate cell damage (red and black arrows). Mitochondrial abnormalities together with cytoskeletal 
alterations are also involved in AbAs exacerbated proliferation and cytoskeleton instability both likely 
underlying the absence of contact inhibition and invasive phenotype as well as S100β-dependent inflammation 
cascades (green and yellow arrows). Progressive loss of the glutamate transporter GLT1 causes decreased 
glutamate uptake becoming neurons more expose to glutamate excitoxicity. Altered signaling and disturbed 
autophagia and proteasome functions caused the release of stress granules and soluble neurotoxins as well as the 
accumulation of cell detritus and inclusion bodies (violet and blue arrows). Finally, the lack of mitochondrial 
potential (represented as Ψ) caused increased glycolysis and deficient anaplerosis that alters the trophic and 
energetic support to neurons and oligodendrocytes (light blue).
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by a blockade of NFkB activation may have positive results, moreover because 
NFkB is downstream to S100β [54]. For example, FDA has been approved a drug 
called mitoxantrone for multiple sclerosis treatment because it inhibited produc-
tion of IL-12 and IL-23 and suppressed the expression of C-reactive protein by 
astrocytes in culture and LPS induction of NFkB DNA-binding activity in primary 
astrocytes, suggesting a novel mechanism that suppresses the expression of 
astrocytic pro-inflammatory molecules helping to modulate inflammatory diseases 
[95]. However, as AbAs seem to loss S100β at higher passages, neuroprotection by 
targeting this via might be successful only during asymptomatic stages. Targeting 
neuroinflammation, recently, it has been shown that the tyrosine kinase inhibitor 
(masitinib) that is used to control cancer cell proliferation reduced the emergence 
of aberrant glial cells in the degenerating spinal cord of SOD1G93A paralytic rats 
and delay disease progression [87]. Authors proposed that masitinib acts prevent-
ing the appearance of aberrant glial phenotypes, likely through the inhibition of 
CSF-1R kinase which activation potentiates inflammatory phenotypes and glial 
reactivity, and that are particularly effective on proliferating but not on post-
mitotic cells [96]. Furthermore, masitinib also prevented astrocyte-induced motor 
neuron death in cell cultures [97], suggesting that neuroprotection can be achieved 
through different pathways. In accordance, other report has shown that CSF-1R 
blockade with the drug GW2580 administered to ALS mice several weeks before 
paralysis onset decreased both microgliosis and slowed disease progression [98], 
thus opening a wider avenue to treat aberrant glial phenotypes. Finally, although 
molecular genetic techniques devoted to switch genes on or off, or to edit their 
nucleotide sequences, once developed and approved can be effective therapeutic 
tools to the inherited ALS forms, pharmacological approaches directed against 
aberrant glial phenotypes may help to control disease progression in a wider range 
of patients.
5. Conclusions
All data reviewed here suggest that aberrant astrocytes or more generally, 
aberrant glial cells, are among the most important players in CNS damage causing 
deleterious effects through many potential patho-mechanisms, mostly sustained 
on their exacerbated proliferation together with their unprecedented neurotoxic-
ity. Therefore, controlling these populations seems at least equally important than 
maintenance or restoration of homeostatic astrocyte functions to achieve CNS 
protection and repair. Moreover, AbAs seemed a better pharmacological target than 
astrocytes, since therapeutic approaches focused on astrocytes have to be carefully 
tailored taking into account their multiple faces, moreover in the context of neuro-
degeneration where several cell types are involved. Future investigation should aim 
to elucidate if AbAs can indeed be feasible targets to avoid initiation, progression or 
outcome of neurodegeneration.
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